GPR39 is heavily associated with the pathogenesis of neurological disorders, including Alzheimer's disease (AD). Given its role as a zinc sensor—and because zinc dyshomeostasis is a hallmark of Alzheimer's—scientists have developed the first GPR39-imaging PET radiotracer ( [11C]TM-N1324 ) to track the receptor's activity in living brains. This tool is groundbreaking, as it allows researchers to study GPR39 levels in vivo, potentially enabling early diagnosis and treatment monitoring for AD patients. Directly targeting GPR39 is now being explored as a pharmacotherapy for the zinc dysregulation observed in Alzheimer's disease.
In the field of socio-anthropology and international development, GRET-39